Petra Acquisition Inc.

Revelation would return to holders with an identical Exchange Cap vote in March 2026 on a January 2026 engagement letter, so this December meeting is one step in a repeating cycle of warrant financings each exceeding the Nasdaq 20% threshold. Each approval permanently removes a cap that exists to protect existing holders from exactly this dilution. The Petra trust was released at the de-SPAC, leaving no floor beneath the stock absorbing it.

This is the first of at least three identical Exchange Cap votes Revelation would call within six months, each tied to a fresh warrant engagement letter - September 2025, then December 2025, then March 2026. Each approval permanently lifts the Nasdaq 20% protection for another financing tranche, so holders face serial dilution from a company returning to the market roughly every quarter. The Petra trust was released at the de-SPAC.

The company states directly that its cash will not be sufficient, while carrying an unresolved Nasdaq minimum bid price deficiency dating to October 2024 and a float of just 2,029,796 shares. That combination forces repeated dilutive warrant financings, which is exactly what followed - three separate Nasdaq Exchange Cap votes between September 2025 and March 2026. The Petra trust was released at the de-SPAC, so there is no floor.

The company is failing two separate Nasdaq tests at once. On October 16, 2024 it received a Minimum Bid Price Delist Letter from the listing qualifications staff, and it is also out of compliance with the Stockholders' Equity Requirement for The Nasdaq Capital Market and with both alternatives — market value of listed securities of at least $35 million, or net income of $500,000 from continuing operations in the most recent fiscal year or two of the last three. Stockholders' equity was about $2.67 million.

Consideration is a fixed block rather than a ratio: Petra acquires all of Revelation's outstanding equity interests for an aggregate of 10,500,000 Merger Consideration Shares, and each Revelation common, Series A Preferred and Series A-1 Preferred share receives that block divided by the Fully Diluted Company Shares, so Revelation's own holders absorb any dilution among themselves. The parties agreed a pre-money valuation of Revelation of $105 million, while the Rule 457(f)(2) fee rests on par value at $1,284.31 and $0.14.

Revelation is a private Delaware company with no market for its securities and an accumulated deficit, so under Rule 457(f)(2) the offering price is one-third of the aggregate par value of the securities to be exchanged, including those issuable on exercise of options — which is how a transaction the parties struck at a $105 million pre-money valuation carries a fourteen-cent fee. The 10,500,000 Merger Consideration Shares are the whole of what Revelation's equityholders receive, divided among them by the Fully Diluted Company Shares.

The $1,284.31 is a fee convention, not a valuation. Revelation is a private Delaware company, no market exists for its securities and it has an accumulated deficit, so Rule 457(f)(2) prices the registration at one-third of the aggregate par value of the Revelation securities to be exchanged, including those issuable on exercise of options. Nothing in this table indicates what Petra is paying, and the only usable number in it is the 10,500,000 share count.

10,500,000 shares is a small registered ceiling, and it is the only usable number in the table: the $1,284.31 is a par-value computation for a private target rather than a valuation of anything. Equity plan participants are inside that ceiling alongside Revelation's stockholders, so the option overhang is not additional to it. Petra's common stock carries a par value of $0.001, ten times the $0.0001 most vehicles in this set use, which is why the par-based fee is larger than some comparable ones.

What changed: Revelation Biosciences, Inc. (Nasdaq: REVB) furnished a press release reporting results for the three and six months ended June 30, 2026. Cash and equivalents were $11.5 million against $10.7 million at December 31, 2025, the increase attributed to net proceeds from the January 2026 warrant inducement offset by operating cash use, and the company states its current cash is sufficient to fund operations through the first quarter of 2027. Net cash used in operating activities was $2.6 million for the quarter against $1.9 million. Why it matters: A stated runway through the first quarter of 2027 against a $2.6 million quarterly burn and $11.5 million of cash is about four quarters, and the pivotal trial it must fund has not yet begun enrolling. The prior-year per-share figures of $28.04 and $54.39 against this year's $0.87 and $3.41 are the reverse-split arithmetic, not an improvement in loss.

What changed: The 10-Q filed under Commission file number 001-39603 is that of Revelation Biosciences, Inc. (Nasdaq: REVB) for the quarter ended June 30, 2026, with 3,983,416 shares outstanding as of August 3, 2026. The registered redeemable warrants are described on the cover as each exercisable for a 1/201,600th share of common stock at an exercise price of $2,318,400.00 per share. Cash was $11,482,792 against $10,700,331 at December 31, 2025, total assets $12,497,932 and total liabilities $2,430,946, leaving stockholders' equity of $10,066,986 against an accumulated deficit of $55,751,722. Why it matters: A warrant that takes 201,600 warrants and $2,318,400.00 per share to buy one share is what an $11.50 SPAC warrant becomes after successive reverse splits — it is arithmetically incapable of being exercised. The company funds itself by repricing warrants downward and issuing new ones, and the accounting cost of that shows up as $5.7 million of deemed dividends that nearly doubles the reported loss to common holders.

What changed: Revelation Biosciences, Inc., the Petra Acquisition Inc. successor, entered a Rights Agreement dated July 10, 2026 with Continental Stock Transfer & Trust Co. as rights agent, filed as Exhibit 4.1. The agreement provides for the issuance of rights and right certificates, sets a purchase price and expiration date for exercise, makes preferred shares available for issuance on exercise, and includes adjustment provisions on consolidation, merger or sale of assets or earning power, together with redemption and exchange mechanics and board determination powers. Why it matters: A rights agreement with preferred shares reserved on exercise is a shareholder rights plan — a poison pill. Its purpose is to make an unapproved accumulation prohibitively dilutive, so it is adopted when a board expects a hostile stake-building or a takeover attempt. For former PAIC holders that means the board has taken control of who can acquire the company, and any bid must now be negotiated with the board rather than made to shareholders directly. The trigger threshold is in the agreement rather than the captured text.

What changed: Revelation Biosciences, Inc. (successor to SPAC Petra Acquisition Inc.) called its 2026 annual meeting for June 24, 2026 at 12:00 p.m. ET by Zoom, record date April 30, 2026, when only 3,908,420 shares of common stock were outstanding. The proxy discloses three reverse stock splits in twelve months: 1-for-16 effected January 28, 2025, after which Nasdaq confirmed on February 19, 2025 that minimum bid price compliance was regained; 1-for-3 effected July 7, 2025 after a June 23, 2025 special meeting; and 1-for-4 effected January 28, 2026. Why it matters: Three reverse splits inside a single year, each undertaken to regain or hold the Nasdaq minimum bid price, is the clearest possible evidence that the share price keeps falling back below $1.00 after every mechanical fix. The share count is down to 3.9 million, so each new financing at a depressed price is proportionally devastating to existing holders and likely forces yet another split. Legacy Petra SPAC holders who converted at the business combination have watched their position compressed by a cumulative factor measured in the hundreds.